1. Thompson A, Winsper C, Marwaha S, et al. Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review. BJPsych Open. 2018 Jul;4(4):215–25.
2. Emsley R. Antipsychotic maintenance treatment in schizophrenia and the importance of preventing relapse. World Psychiatry. 2018 Jun;17(2):168–9.
3. Hui CLM, Honer WG, Lee EHM, et al. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial. Lancet Psychiatry. 2018 May 1;5(5):432–42.
4. Goff DC, Falkai P, Fleischhacker WW, et al. The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia. Am J Psychiatry. 2017 May 5;174(9):840–9.
5. Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2020;(8). DOI: 10.1002/14651858.CD008016.pub3
6. Crockford D, Addington D. Canadian Schizophrenia Guidelines: Schizophrenia and Other Psychotic Disorders with Coexisting Substance Use Disorders. Can J Psychiatry. 2017 Sep;62(9):624-634. doi: 10.1177/0706743717720196. PMID: 28886671; PMCID: PMC5593250.
7. Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149–60.
8. Wils RS, Gotfredsen DR, Hjorthøj C, Austin SF, Albert N, et al. Antipsychotic medication and remission of psychotic symptoms 10 years after a first-episode psychosis. Schizophr Res. 2017 Apr 1;182:42–8.
9. Gaebel W, Stricker J, Riesbeck M. The long-term antipsychotic treatment of schizophrenia: A selective review of clinical guidelines and clinical case examples. Schizophr Res. 2020 Nov 1;225:4–14.
10. Kotov R, Fochtmann L, Li K, et al. Declining Clinical Course of Psychotic Disorders Over the Two Decades Following First Hospitalization: Evidence From the Suffolk County Mental Health Project. Am J Psychiatry. 2017 Nov 1;174(11):1064-1074. doi: 10.1176/appi.ajp.2017.16101191. Epub 2017 Aug 4. PMID: 28774193; PMCID: PMC5767161.
11. Tiihonen J, Mittendorfer-Rutz E, Majak M, et al. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia. JAMA Psychiatry. 2017 Jul;74(7):686–93.
12. Correll CU, Solmi M, Veronese N, et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large‐scale meta‐analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry. 2017 Jun;16(2):163–80.
13. Cadena EJ, White DM, Kraguljac NV, et al. Cognitive control network dysconnectivity and response to antipsychotic treatment in schizophrenia. Schizophr Res. 2019 Feb 1;204:262–70.
14. Husa AP, Moilanen J, Murray GK,et al. Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort. Psychiatry Res. 2017 Jan 1;247:130–8.
15. Scheggia D, Mastrogiacomo R, Mereu M, et al. Variations in Dysbindin-1 are associated with cognitive response to antipsychotic drug treatment. Nat Commun. 2018 Jun 11;9(1):2265.